Since its funded initiation in April, 1999, the Pediatric Brain Tumor Consortium (PBTC) has successfully pursued its mission to study novel therapeutic approaches for children with brain tumors. The Consortium and its member institutions propose to continue progress in its major goals: to identify new treatments for these diseases including those that are technically challenging; to ensure that laboratory discoveries relevant to children with brain cancers are rapidly translated into the clinical setting; to define the role of neuroimaging in the setting of novel approaches. Research plans are proposed in the major pediatric brain tumor types, emphasizing those tumor systems that are associated with poor outcome measured by disease control or quality of life. The PBTC is a highly interactive, multidisciplinary group dedicated to further translating the recently identified biological understandings of CNS tumors into tests of new, targeted biological therapies. The Consortium is able to pursue unique clinical trials in new cytototic and anti-angiogenic agents, in addition to local delivery trials that address intrathecal regional chemotherapy and direct neurosurgical drug administration; a study testing intra-perilesional administration of a new biological conjugate by enhanced convection delivery is convection delivery is awaiting final FDA approval. Trials include Phase I and II pharmacologic agents, alone or in combination with irradiation and studies include major research objectives related to neuroimaging, pharmacokinetic and key biological questions. The PBTC has developed an efficient, technologically sophisticated Operations and Biostatistics Center (OBC) that facilitates protocol development and regulatory review while overseeing and reporting protocol conduct within the 11-member group. The Consortium developed and secured initial funding for a Neuroimaging Center (NIC) as a resource for correlative research and will reap the fruits of these investments in the coming grant period. The Consortium is supported by a unique, completely electronic distributed database system, and the first successfully developed, systematically utilized electronic imaging submission and distribution system linking member institutions withy the Boston NIC via the OBC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA081457-09
Application #
7216342
Study Section
Special Emphasis Panel (ZCA1-GRB-F (J1))
Program Officer
Smith, Malcolm M
Project Start
1999-04-01
Project End
2009-03-31
Budget Start
2007-04-05
Budget End
2008-03-31
Support Year
9
Fiscal Year
2007
Total Cost
$2,498,325
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Kilburn, Lindsay B; Kocak, Mehmet; Baxter, Patricia et al. (2018) A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 65:
Banerjee, Anuradha; Jakacki, Regina I; Onar-Thomas, Arzu et al. (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135-1144
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Gururangan, Sridharan; Reap, Elizabeth; Schmittling, Robert et al. (2017) Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunol Immunother 66:1589-1595
Zukotynski, Katherine A; Vajapeyam, Sridhar; Fahey, Frederic H et al. (2017) Correlation of18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med 58:1264-1269
Han, Kelong; Peyret, Thomas; Quartino, Angelica et al. (2016) Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 81:148-60
Poussaint, Tina Young; Vajapeyam, Sridhar; Ricci, Kelsey I et al. (2016) Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 18:725-34
Salloum, Ralph; Hummel, Trent R; Kumar, Shiva Senthil et al. (2016) A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol 129:443-451
Mulkern, Robert V; Ricci, Kelsey I; Vajapeyam, Sridhar et al. (2015) Pediatric brain tumor consortium multisite assessment of apparent diffusion coefficient z-axis variation assessed with an ice-water phantom. Acad Radiol 22:363-9
Robinson, Giles W; Orr, Brent A; Wu, Gang et al. (2015) Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol 33:2646-54

Showing the most recent 10 out of 65 publications